Can CM272, a dual G9a/DNMT1 inhibitor, be used as an immunomodulating agent to enhance the efficacy of existing immunotherapies in melanoma?

Onderzoeksoutput: Poster

2 Downloads (Pure)
Originele taal-2English
StatusUnpublished - 2019
EvenementBACR: novel combination strategies for cancer treatment - Antwerp, Belgium
Duur: 1 feb 2019 → …

Conference

ConferenceBACR: novel combination strategies for cancer treatment
LandBelgium
StadAntwerp
Periode1/02/19 → …

Citeer dit